JP2012100677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012100677A5 JP2012100677A5 JP2011290449A JP2011290449A JP2012100677A5 JP 2012100677 A5 JP2012100677 A5 JP 2012100677A5 JP 2011290449 A JP2011290449 A JP 2011290449A JP 2011290449 A JP2011290449 A JP 2011290449A JP 2012100677 A5 JP2012100677 A5 JP 2012100677A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- further embodiment
- seq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66017705P | 2005-03-10 | 2005-03-10 | |
| US60/660,177 | 2005-03-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500966A Division JP4949373B2 (ja) | 2005-03-10 | 2006-03-09 | 抗メソテリン抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168325A Division JP5788443B2 (ja) | 2005-03-10 | 2013-08-13 | 抗メソテリン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012100677A JP2012100677A (ja) | 2012-05-31 |
| JP2012100677A5 true JP2012100677A5 (enExample) | 2013-03-28 |
| JP5378497B2 JP5378497B2 (ja) | 2013-12-25 |
Family
ID=36992268
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500966A Expired - Lifetime JP4949373B2 (ja) | 2005-03-10 | 2006-03-09 | 抗メソテリン抗体 |
| JP2011290449A Expired - Lifetime JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
| JP2013168325A Expired - Lifetime JP5788443B2 (ja) | 2005-03-10 | 2013-08-13 | 抗メソテリン抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500966A Expired - Lifetime JP4949373B2 (ja) | 2005-03-10 | 2006-03-09 | 抗メソテリン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168325A Expired - Lifetime JP5788443B2 (ja) | 2005-03-10 | 2013-08-13 | 抗メソテリン抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7592426B2 (enExample) |
| EP (2) | EP1861425B1 (enExample) |
| JP (3) | JP4949373B2 (enExample) |
| AU (2) | AU2006223301B2 (enExample) |
| CA (1) | CA2600505C (enExample) |
| ES (2) | ES2386367T3 (enExample) |
| WO (1) | WO2006099141A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007500508A (ja) * | 2003-07-29 | 2007-01-18 | モルフォテック、インク． | 抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法 |
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| KR100694508B1 (ko) * | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| US7943133B2 (en) * | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
| US7795411B2 (en) | 2006-10-05 | 2010-09-14 | Fred Hutchinson Cancer Research Center | Vectors for expressing in vivo biotinylated recombinant proteins |
| WO2008057461A2 (en) * | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| CA2700860C (en) * | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| CN104151429B (zh) * | 2007-11-26 | 2018-07-10 | 拜耳知识产权有限责任公司 | 抗-间皮素抗体及其用途 |
| EP2257572A1 (en) * | 2008-03-27 | 2010-12-08 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Human anti-mesothelin monoclonal antibodies |
| JP2010014691A (ja) * | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
| AU2010230063B2 (en) * | 2009-03-24 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
| UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| CA2795043C (en) * | 2010-03-30 | 2019-04-23 | Janssen Biotech, Inc. | Humanized il-25 antibodies |
| WO2012087962A2 (en) * | 2010-12-20 | 2012-06-28 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| US10233240B1 (en) * | 2011-04-18 | 2019-03-19 | The Regents Of The University Of California | Methods for treating cholestatic liver fibrosis |
| BR112013028537A2 (pt) | 2011-05-06 | 2017-01-17 | Us Gov Health & Human Serv | imunotoxina recombinante que visa a mesotelina |
| KR102084806B1 (ko) | 2012-02-17 | 2020-03-04 | 시애틀 지네틱스, 인크. | 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도 |
| RS58910B1 (sr) | 2012-03-20 | 2019-08-30 | Biogen Ma Inc | Antitela koja neutrališu virus jcv |
| US9567391B2 (en) | 2012-03-20 | 2017-02-14 | Biogen Ma Inc. | JCV neutralizing antibodies |
| US9359447B2 (en) | 2012-03-23 | 2016-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| EP2888282B1 (en) * | 2012-08-21 | 2018-03-14 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| BR112017010513A2 (pt) | 2014-11-20 | 2018-04-03 | F. Hoffmann-La Roche Ag | ?cadeias leves comuns e métodos de uso? |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| US10793641B2 (en) * | 2015-08-21 | 2020-10-06 | Carsgen Therapeutics Co., Ltd. | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| US20170096485A1 (en) * | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
| BR112018006811A2 (en) | 2015-10-06 | 2018-10-16 | Regents Of The University Of Minnesota | therapeutic compounds and methods |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
| SG11201808085WA (en) * | 2016-03-22 | 2018-10-30 | Hoffmann La Roche | Protease-activated t cell bispecific molecules |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CN109715808A (zh) | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| EP3448421B1 (en) * | 2016-04-29 | 2021-11-03 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| SG11201810591VA (en) * | 2016-05-27 | 2018-12-28 | Abbvie Biotherapeutics Inc | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| TW201831513A (zh) | 2016-06-20 | 2018-09-01 | Ｆ星貝塔有限公司 | 結合物件(一) |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CN110267677A (zh) | 2016-08-01 | 2019-09-20 | 诺华股份有限公司 | 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症 |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| FI3548515T3 (fi) | 2016-12-01 | 2026-03-04 | Regeneron Pharma | Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2018387741B2 (en) | 2017-12-19 | 2025-09-25 | Invox Pharma Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3806889A4 (en) * | 2018-06-18 | 2022-07-13 | Anwita Biosciences, Inc. | CYTOKI FUSION PROTEINS AND USES THEREOF |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| TW202026006A (zh) | 2018-08-30 | 2020-07-16 | 美商Ｔｃｒ２療法股份有限公司 | 使用融合蛋白進行tcr再程式化之組成物及方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN120535653A (zh) | 2018-10-19 | 2025-08-26 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| WO2020092631A1 (en) * | 2018-10-31 | 2020-05-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for detecting and treating cancers characterized by expression of mesothelin |
| MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| CN112321714B (zh) * | 2019-01-08 | 2022-06-28 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其核酸分子 |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| WO2020257407A1 (en) * | 2019-06-19 | 2020-12-24 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| TWI884192B (zh) | 2019-12-05 | 2025-05-21 | 美商西健公司 | 抗αＶβ６抗體及抗體-藥物結合物 |
| AU2020405230A1 (en) | 2019-12-20 | 2022-06-23 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| TW202135859A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 組合療法 |
| KR20230024967A (ko) | 2020-06-11 | 2023-02-21 | 노파르티스 아게 | Zbtb32 억제제 및 이의 용도 |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024226827A2 (en) | 2023-04-25 | 2024-10-31 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2121792T3 (es) | 1990-10-12 | 1998-12-16 | Us Health | Anticuerpo monoclonal. |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US6074643A (en) | 1993-09-09 | 2000-06-13 | Cli Oncology, Inc. | Site-directed chemotherapy of metastases |
| US6191268B1 (en) | 1993-12-17 | 2001-02-20 | Dana-Farber Cancer Institute | Compositions and methods relating to DNA mismatch repair genes |
| EP0749496A4 (en) | 1994-01-27 | 1999-03-03 | Human Genome Sciences Inc | HUMAN DNA MALFUNCTION REPAIR PROTEINS |
| DE19513676A1 (de) | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| AU703769B2 (en) | 1996-01-05 | 1999-04-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Mesothelium antigen and methods and kits for targeting it |
| SK150298A3 (en) | 1996-05-04 | 1999-04-13 | Zeneca Ltd | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| ES2248914T3 (es) | 1997-08-29 | 2006-03-16 | Corixa Corporation | Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos. |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| CA2318576C (en) | 1997-12-01 | 2009-04-14 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6146894A (en) | 1998-04-14 | 2000-11-14 | The Johns Hopkins University | Method for generating hypermutable organisms |
| US7745159B2 (en) * | 1999-02-26 | 2010-06-29 | Nathalie B Scholler | Methods and compositions for diagnosing carcinomas |
| US6365410B1 (en) | 1999-05-19 | 2002-04-02 | Genencor International, Inc. | Directed evolution of microorganisms |
| ATE401348T1 (de) | 1999-05-27 | 2008-08-15 | Us Gov Health & Human Serv | Immunokonjugate mit hoher bindungsaffinität |
| ES2263626T3 (es) | 2000-06-05 | 2006-12-16 | Corixa Corporation | Peptidos lider para potenciar la secrecion de proteina recombinante a partir de una celula hospedante. |
| US6808894B1 (en) | 2000-11-07 | 2004-10-26 | Morphotek, Inc. | Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics |
| JP5036119B2 (ja) | 2001-01-15 | 2012-09-26 | モーフオテク・インコーポレーテツド | ミスマッチ修復の化学阻害剤 |
| AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| EE200300569A (et) | 2001-05-18 | 2004-04-15 | Boehringer Ingelheim International Gmbh | CD44v6-spetsiifilised antikehad |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| EP1421111A2 (en) | 2001-08-08 | 2004-05-26 | Incyte Genomics, Inc. | Proteins associated with cell growth differentiation, and death |
| ATE489474T1 (de) | 2002-07-19 | 2010-12-15 | Morphotek Inc | Verfahren zur erzeugung verbesserter antikörper produzierender zellinien mit verbesserten wachstumseigenschaften |
| EP1651675A1 (en) * | 2003-08-05 | 2006-05-03 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
| EP1861425B1 (en) * | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| AU2006241099B2 (en) | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
-
2006
- 2006-03-09 EP EP06737748A patent/EP1861425B1/en not_active Expired - Lifetime
- 2006-03-09 EP EP10180413.6A patent/EP2322560B1/en not_active Expired - Lifetime
- 2006-03-09 JP JP2008500966A patent/JP4949373B2/ja not_active Expired - Lifetime
- 2006-03-09 ES ES06737748T patent/ES2386367T3/es not_active Expired - Lifetime
- 2006-03-09 AU AU2006223301A patent/AU2006223301B2/en not_active Expired
- 2006-03-09 WO PCT/US2006/008598 patent/WO2006099141A2/en not_active Ceased
- 2006-03-09 CA CA2600505A patent/CA2600505C/en not_active Expired - Lifetime
- 2006-03-09 ES ES10180413T patent/ES2429340T3/es not_active Expired - Lifetime
- 2006-03-09 US US11/373,546 patent/US7592426B2/en active Active
-
2009
- 2009-08-21 US US12/545,369 patent/US8206710B2/en active Active
-
2011
- 2011-01-24 AU AU2011200251A patent/AU2011200251B2/en not_active Expired
- 2011-12-29 JP JP2011290449A patent/JP5378497B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-21 US US13/476,656 patent/US8481703B2/en not_active Expired - Lifetime
-
2013
- 2013-03-13 US US13/799,766 patent/US8658173B2/en not_active Expired - Lifetime
- 2013-08-13 JP JP2013168325A patent/JP5788443B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-06 US US14/148,011 patent/US9115197B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012100677A5 (enExample) | ||
| JP7270522B2 (ja) | 増殖分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体 | |
| RU2764031C2 (ru) | Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью | |
| TWI708788B (zh) | 雙特異性抗體 | |
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| JP2008532523A5 (enExample) | ||
| JP2019500020A (ja) | グリカン相互作用化合物および使用方法 | |
| JP6574257B2 (ja) | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 | |
| EP3322715A1 (en) | Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof | |
| JP2022517989A (ja) | 細胞内部移行をモジュレートするための組成物および方法 | |
| RU2014108309A (ru) | Антиполиубиквитиновые антитела и способы применения | |
| CN102099376A (zh) | 针对her2的细胞外结构域2和3的抗体 | |
| Zeng et al. | A fully human anti-CD47 blocking antibody with therapeutic potential for cancer | |
| JP2014515600A5 (enExample) | ||
| JP2024514855A (ja) | Ｄｌｌ３に対する結合分子及びその使用 | |
| MD3310816T2 (ro) | Imunoglobuline conjugate Cys80 | |
| WO2024008112A1 (en) | Anti-ror1 antibodies | |
| Gunaratne et al. | The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library | |
| CN118103071A (zh) | Herv-k抗体治疗剂 | |
| Zhang et al. | A coiled coil-based pre-targeting drug delivery system for precise treatment of breast cancer | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| Moricoli et al. | Isolation of a new human scFv antibody recognizing a cell surface binding site to CEACAM1. Large yield production, purification and characterization in E. coli expression system | |
| Karaan | Antibody engineering to evaluate binding, internalisation, and intracellular routing of tumour-targeting fusion proteins | |
| WO2021229104A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| Gunaratne et al. | Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library |